Related Experiment Videos
Thrombotic thrombocytopenic purpura
Bérangère S Joly1,2,3, Paul Coppo3,4,5, Agnès Veyradier1,2,3
1Service d'Hématologie Biologique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France.
Blood
|April 19, 2017
Summary
Thrombotic thrombocytopenic purpura (TTP) is a rare microangiopathy caused by ADAMTS13 deficiency. Prompt diagnosis and treatment, including plasma exchange and immune modulators, are crucial for managing this life-threatening condition.
Area of Science:
- Hematology
- Immunology
- Genetics
Background:
- Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening thrombotic microangiopathy.
- It is characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and organ ischemia.
- TTP is specifically linked to severe deficiency of ADAMTS13, the von Willebrand factor-cleaving protease.
Purpose of the Study:
- To review the etiology, clinical features, and management of TTP.
- To highlight the importance of rapid diagnosis and current therapeutic strategies.
- To discuss emerging therapies and the need for long-term patient follow-up.
Main Methods:
- Review of current literature on TTP.
- Analysis of diagnostic criteria and treatment protocols.
- Evaluation of novel therapeutic agents and management strategies.
Main Results:
- TTP is primarily caused by acquired ADAMTS13 autoantibodies, but inherited forms exist.
- First-line treatment involves plasma exchange and steroids; rituximab is used for autoimmune cases.
- Refractory TTP may require intensive therapies, and new drugs show promise.
Conclusions:
- Early recognition and treatment of TTP are critical for patient outcomes.
- Long-term follow-up is essential for managing relapses and sequelae.
- Continued research and patient registries are needed to improve TTP management.